Tergus Pharma
Durham, NC
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Tergus Pharma
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Durham, NC
- Modalities
- Topical Drug Product Development, IVRT, IVPT, Semisolid GMP Manufacturing, Skin Permeation, Dermatology CDMO, Hormone and High Potent Compound Manufacturing
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Tergus Pharma
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesTopical Drug Product Development, IVRT, IVPT, Semisolid GMP Manufacturing, Skin Permeation, Dermatology CDMO, Hormone and High Potent Compound Manufacturing
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (7 modalities)
Recent News 10 articles
Performance Cell picked up by private equity firm, rebrands as Cellipont Bioservices - Fierce Pharma
Private Equity Healthcare Acquisitions – July 2024 - Private Equity Stakeholder Project PESP
Prominent CDMO Tergus Pharma Officially Opens New Headquarters - PRWeb
Investment firm Great Point Partners scoops up German CDMO Lyocontract - Fierce Pharma
Tergus Pharma merges with fellow dermatology CDMO MedPharm - Fierce Pharma
Tergus Pharma to become full-fledged CDMO with new manufacturing facility - Fierce Pharma
MedPharm, Ltd. and Tergus Pharma Merger Forms Topical and Transdermal CDMO Leader - PR Newswire
Medpharm Announces Merger with Tergus Pharma - Contract Pharma
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
Durham CDMOs merge backed by private equity - The Business Journals
Frequently Asked Questions About Tergus Pharma
What is Tergus Pharma's CDMO Signal Score?
Tergus Pharma has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Tergus Pharma for a manufacturing program?
Use the free AI matchmaker to compare Tergus Pharma against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
MedPharm (Tergus Pharma)
Guildford, United Kingdom (US operations: Durham, NC)
Topical Drug Product Development, IVRT, IVPT, Semisolid GMP Manufacturing, Transdermal, Dermatology CDMO, Creams/Gels/Ointments/Lotions
CPL CDMO (Skin Lab)
Mississauga, ON, Canada
IVRT, IVPT, Topical Drug Product Development, Semisolid Formulation, Transdermal, Bioequivalence Testing